CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program
09 déc. 2022 11h00 HE
|
CURE Media Group
CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients,...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
01 déc. 2022 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists Will Gather for the 2023 Tandem Meetings
30 nov. 2022 12h00 HE
|
American Society for Transplantation and Cellular Therapy (ASTCT)
CHICAGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® will connect the international community of hematopoietic...
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
15 nov. 2022 08h32 HE
|
ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
08 nov. 2022 08h35 HE
|
ExCellThera
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy...
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
04 nov. 2022 09h30 HE
|
ExCellThera
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
Mendus AB: Mendus presenterar flera abstracts på ASH 2022, inklusive en muntlig presentation av uppdaterade AML-överlevnadsresultat från fas 2-studien ADVANCE II
03 nov. 2022 09h10 HE
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, eller “Bolaget”), ett bioläkemedelsföretag fokuserat på immunterapier som adresserar tumöråterfall, kan idag meddela att uppdaterade resultat från bolagets pågående...
Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial
03 nov. 2022 09h10 HE
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that updated results from the Company’s...
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
27 oct. 2022 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
24 oct. 2022 12h00 HE
|
ASTCT
MINNEAPOLIS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International...